These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 7618528

  • 1. Neurotoxicity of MPTP and uptake of MPPT into dopamine and norepinephrine neurons in mice.
    Lee EH, Lu KT.
    Adv Exp Med Biol; 1995; 363():29-46. PubMed ID: 7618528
    [No Abstract] [Full Text] [Related]

  • 2. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
    Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T.
    J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
    [Abstract] [Full Text] [Related]

  • 3. Uptake inhibition protects nigro-striatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenylpyridine (MPP+) in mice.
    Sundström E, Goldstein M, Jonsson G.
    Eur J Pharmacol; 1986 Nov 19; 131(2-3):289-92. PubMed ID: 3493159
    [Abstract] [Full Text] [Related]

  • 4. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO.
    Eur J Neurosci; 2008 Jul 19; 28(1):41-50. PubMed ID: 18662333
    [Abstract] [Full Text] [Related]

  • 5. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium.
    Miller DB, Reinhard JF, Daniels AJ, O'Callaghan JP.
    J Neurochem; 1991 Aug 19; 57(2):541-9. PubMed ID: 1649252
    [Abstract] [Full Text] [Related]

  • 6. Nigral and striatal comparative study of the neurotoxic action of 1-methyl-4-phenylpyridinium ion: involvement of dopamine uptake system.
    Santiago M, Machado A, Cano J.
    J Neurochem; 1996 Mar 19; 66(3):1182-90. PubMed ID: 8769882
    [Abstract] [Full Text] [Related]

  • 7. Plasticity of the nigrostriatal system in MPTP-treated mice. A biochemical and morphological correlation.
    Cruz-Sanchez FF, Cardozo A, Ambrosio S, Tolosa E, Mahy N.
    Mol Chem Neuropathol; 1993 Mar 19; 19(1-2):163-76. PubMed ID: 8103334
    [Abstract] [Full Text] [Related]

  • 8. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice.
    Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Launay JM, Cohen-Salmon C, Hirsch EC.
    Neurobiol Dis; 2003 Nov 19; 14(2):218-28. PubMed ID: 14572444
    [Abstract] [Full Text] [Related]

  • 9. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A, Fascetti F, Corsini GU, Piccardi MP.
    Exp Neurol; 1994 May 19; 127(1):54-61. PubMed ID: 8200437
    [Abstract] [Full Text] [Related]

  • 10. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
    Kuhlmann AC, Guilarte TR.
    Toxicol Sci; 1999 Mar 19; 48(1):107-16. PubMed ID: 10330690
    [Abstract] [Full Text] [Related]

  • 11. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
    Melamed E, Rosenthal J, Cohen O, Globus M, Uzzan A.
    Eur J Pharmacol; 1985 Oct 08; 116(1-2):179-81. PubMed ID: 3876943
    [Abstract] [Full Text] [Related]

  • 12. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D, Samantaray S, Mohanakumar KP.
    Synapse; 2003 Oct 08; 50(1):7-13. PubMed ID: 12872288
    [Abstract] [Full Text] [Related]

  • 13. Creatine and cyclocreatine attenuate MPTP neurotoxicity.
    Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF.
    Exp Neurol; 1999 May 08; 157(1):142-9. PubMed ID: 10222117
    [Abstract] [Full Text] [Related]

  • 14. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice.
    Hu SC, Chang FW, Sung YJ, Hsu WM, Lee EH.
    J Pharmacol Exp Ther; 1991 Dec 08; 259(3):1379-87. PubMed ID: 1684822
    [Abstract] [Full Text] [Related]

  • 15. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
    Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM.
    Proc Natl Acad Sci U S A; 1996 May 14; 93(10):4565-71. PubMed ID: 8643444
    [Abstract] [Full Text] [Related]

  • 16. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice.
    Chan P, Di Monte DA, Langston JW, Janson AM.
    J Pharmacol Exp Ther; 1997 Jan 14; 280(1):439-46. PubMed ID: 8996226
    [Abstract] [Full Text] [Related]

  • 17. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
    Fornai F, Alessandrì MG, Torracca MT, Bassi L, Corsini GU.
    J Pharmacol Exp Ther; 1997 Oct 14; 283(1):100-7. PubMed ID: 9336313
    [Abstract] [Full Text] [Related]

  • 18. Free radicals and MPTP-induced selective destruction of substantia nigra compacta neurons.
    Chiueh CC, Rauhala P.
    Adv Pharmacol; 1998 Oct 14; 42():796-800. PubMed ID: 9328018
    [No Abstract] [Full Text] [Related]

  • 19. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP.
    Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez-Espinola S, Andbjer B, Leo G, Medhurst AD, Agnati LF, Fuxe K.
    Brain Res; 2005 Feb 08; 1033(2):216-20. PubMed ID: 15694927
    [Abstract] [Full Text] [Related]

  • 20. MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
    Viaggi C, Vaglini F, Pardini C, Caramelli A, Corsini GU.
    Neuropharmacology; 2009 Jun 08; 56(8):1075-81. PubMed ID: 19298832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.